StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) company profile

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

About Kalaris Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

The company is a clinical-stage biopharmaceutical business focused on developing and commercializing therapeutics for prevalent retinal diseases characterized by substantial unmet medical needs. Its development pipeline centers on treatments for neovascular and exudative eye disorders, specifically neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. Its primary product candidate is TH103, an intravitreally administered anti-vascular endothelial growth factor recombinant fusion protein engineered to enhance intraocular retention and improve durability over existing therapies. Because the company remains in the clinical investigation stage, it currently has no commercialized treatments and primarily directs its clinical efforts toward patients suffering from vision-threatening ocular conditions.

The company retains worldwide rights to develop and commercialize its lead product candidate and plans to establish an internal specialty salesforce upon potential regulatory approval. Its operations center on clinical-stage research and development targeting prevalent conditions that affect millions of patients in the United States, Europe, and worldwide. Specific headquarters location, corporate facility numbers, or administrative office locations are not disclosed in the provided text.

Summary of the business section of Kalaris Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Kalaris Therapeutics, Inc.
Headquarters
Berkeley Heights, NJ
Address
400 Connell Drive, Suite 5500 07922
Phone
(650) 249-2727
Employees
20, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, San Francisco, California

Stock & identifiers

Ticker
KLRS
Former tickers
ALVR until Mar 18, 2025
Exchange
Nasdaq
IPO date
Jul 30, 2020
Shares outstanding
24M, Aug 4, 2026
Public float
$12.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-23 reverse, Jan 16, 2025
SEC CIK
1754068
CUSIP
482929106
ISIN
US4829291065
FIGI
BBG00P80SH34
Share class FIGI
BBG00P80SH43
EIN
83-1971007

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Andrew OxtobySee Remarks, Director–
Vikas SinhaSee Remarks, Director774,118
Diana BrainardChief Executive Officer, Director723,363
Amy O'Leary VandekopVP, Corporate Controller948
Liisa Ann BaykoChief Financial Officer–
Brett R. HagenChief Accounting Officer0
Matthew GallChief Financial Officer–
Matthew FeinsodChief Medical Officer4,030
Edward MillerGeneral Counsel21,575
Laurie KeatingDirector–
Leone D. PattersonDirector–
Morana Jovan-EmbiricosDirector26,603,054
Napoleone FerraraDirector504,000
Anthony P. AdamisDirector–
Srinivas AkkarajuDirector12,948,081
David HallalDirector19,677,546
Michael DybbsDirector–
Samir Chandrakant PatelDirector352,800

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Andrew Oxtoby
$2.57M$4.51M$1.39M$54–
FY2025
Diana Bainard
$0$0$1.39M$54–
FY2025
Vikas Sinha
$1.10M$1.10M$1.39M$54–
FY2024
Andrew Oxtoby
$0$0$721.00K$62–
FY2024
Diana Bainard
$3.03M$2.83M$721.00K$62–
FY2024
Vikas Sinha
$544.40K$456.15K$721.00K$62–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Andrew Oxtoby
President and Chief Executive Officer
$537.73K–$1.69M$344.31K–$2.57M+31%
Matthew Feinsod
Chief Medical Officer
$457.73K–$1.01M$207.64K–$1.67M–
Matthew Gall
Former Chief Financial Officer
$80.83K–$949.28K$34.50K–$1.06M–
Vikas Sinha
AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer
$81.11K–––$1.02M$1.10M+102%
Brett Hagen
Chief Accounting Officer and AlloVir’s former Chief Accounting Officer
$397.30K$67.81K$295.42K$121.51K$557.13K$1.44M+81%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 30, 2020
Offer price
$17.00
Securities offered
16,250,000
Gross proceeds
$276.25M
Exchange
Nasdaq
Lock-up ends (est.)
Jan 26, 2021

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had twenty employees, all of whom were full-time and eleven of whom were engaged in research and development activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 18, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 12, 2025Name changeName changed from Allovir, Inc. to Kalaris Therapeutics, Inc.
Dec 9, 2024MergerRegistration of securities for a merger or exchange offer (S-4)
Feb 12, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 30, 2020IPOInitial public offering priced (424B4 prospectus)
Jul 27, 2020ListingRegistration of securities on an exchange (Form 8-A)
Oct 2, 2018Name changeName changed from ViraCyte, Inc. to Allovir, Inc.

See a number that looks wrong?